Mon. Nov 28th, 2022
Zydus Cadila gets USFDA nod for overactive bladder treatment drug The company has received final approval from the United States Food and Drug Administration (USFDA) to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.